Verve Therapeutics, Inc. (VERV)

6,03 -0,33 (-5,19%) A partir del 02:06PM EDT. Mercado abierto.

Verve Therapeutics, Inc.

201 Brookline Avenue
Suite 601
Cambridge, MA 02215
United States
617 603 0070
https://www.vervetx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 255

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Sekar Kathiresan M.D.	Co-Founder, CEO & Director	973,25k	N/A	1973
Ms. Allison Dorval	CFO & Principal Accounting Officer	711,76k	N/A	1976
Dr. Andrew M. Bellinger M.D., Ph.D.	Chief Scientific Officer	758,29k	N/A	1978
Mr. Andrew D. Ashe J.D.	President, COO & General Counsel	703,85k	N/A	1967
Dr. Kiran Musunuru M.D., M.P.H., Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder	N/A	N/A	N/A
Dr. Anthony Philippakis M.D., Ph.D.	Co-Founder & Scientific Advisory Board Member	7,97k	N/A	N/A
Dr. Barry S. Ticho FACC, M.D., Ph.D.	Co-Founder	N/A	N/A	1961
Mr. Issi Rozen M.B.A.	Co-Founder & Strategic Advisor	N/A	N/A	N/A
Ms. Joan Nickerson M.B.A.	Chief Administrative Officer	N/A	N/A	1969

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Verve Therapeutics, Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 7; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.